Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Dimopoulos, Meletios ^{[1
]}

Weisel, Katja ^{[2
]}

Hungria, Vania ^{[3
]}

Sapra, Sandhya ^{[4
]}

Sule, Neal ^{[4
]}

Li, Mary ^{[4
]}

McKeown, Astrid ^{[5
]}

Kazeem, Gbenga ^{[5
]}

Polinkovsky, Margaret ^{[6
]}

Meunier, Juliette ^{[7
]}

Loubert, Angely ^{[7
]}

Bunod, Laurine ^{[7
]}

Perera, Sue ^{[8
]}

Currie, Brooke ^{[9
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Athens, Greece

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Clin Sao Germano, Dept Hematol, Sao Paulo, Brazil

[4] GSK, Upper Providence, PA USA

[5] GSK, Stevenage, Herts, England

[6] GSK, Durham, NC USA

[7] Modus Outcomes, Lyon, France

[8] GSK, London, England

[9] GSK, Rockville, MD USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-252

引用

页码：S174 / S175

页数：2

共 50 条

[1] Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Palumbo, Antonio
Belch, Andrew
Schey, Stephen
Sonneveld, Pieter
Sternas, Lars
Yu, Xin
Amatya, Ramesh
Monzini, Mara S.
Zaki, Mohamed
Jacques, Christian
Miguel, Jesus San
HAEMATOLOGICA, 2015, 100 (02) : E63 - E67
[2] Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Weisel, Katja
Dimopoulos, Meletios
Moreau, Philippe
Yagci, Munci
Larocca, Alessandra
Kanate, Abraham S.
Vural, Filiz
Cascavilla, Nicola
Basu, Supratik
Johnson, Peter
Byeff, Peter
Hus, Marek
Rodriguez-Otero, Paula
Muelduer, Ercan
Anttila, Pekka
Hayden, Patrick J.
Krauth, Maria-Theresa
Lucio, Paulo
Ben-Yehuda, Dina
Mendeleeva, Larisa
Guo, Shien
Yu, Xin
Grote, Lara
Biyukov, Tsvetan
Dhanasiri, Sujith
Richardson, Paul
LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1850 - 1859
[3] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2017, 130 (10) : 1189 - 1197
[4] Health-Related Quality of Life With Pomalidomide plus Dexamethasone plus Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients
Reece, Donna
Bahlis, Nizar J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Siegel, David S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E277 - E278
[5] A health-related quality-of-life (HRQoL) analysis of pomalidomide plus low-dose dexamethasone plus daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.
Reece, Donna Ellen
Bahlis, Nizar J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo A.
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Siegel, David Samuel DiCapua
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
Dimopoulos, Meletios
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Vorobyev, Vladimir
Quach, Hang
Spicka, Ivan
Radocha, Jakub
Robak, Pawel
Kim, Kihyun
Cavo, Michele
Suzuki, Kazuhito
Wilkes, Jodie
Morris, Kristin
Pompilus, Farrah
Purser, Molly
Philips-Jones, Amy
Zhou, Xiaoou
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Manteca, Maria-Victoria Mateos
Trudel, Suzanne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S9 - S9
[7] Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
Weisel, Katja
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Cocks, Kim
Popa-McKiver, Mihaela
Chen, Clara
Cavo, Michele
BLOOD, 2019, 134
[8] Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Trudel, Suzanne
McCurdy, Arleigh
Sutherland, Heather J.
Louzada, Martha L.
Venner, Christopher P.
Mian, Hira S.
Kotb, Rami
Othman, Ibraheem
Camacho, Fernando
Gul, Engin
Reece, Donna E.
White, Darrell J.
Fu, Molei
BLOOD, 2021, 138
[9] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Stowell, Delia
Gupta, Ira
Wu, Frank S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
[10] Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
Houghton, Katherine
Dimopoulos, Meletios A.
Lin, Peggy
Guillonneau, Sophie
Bury, Denise
Attal, Michel
Richardson, Paul G.
Delforge, Michel
BLOOD, 2019, 134

← 1 2 3 4 5 →